
    
      PRIMARY OBJECTIVES:

      I. Any episode of major bleeding including fatal bleeding or clinically relevant non-major
      bleeding.

      SECONDARY OBJECTIVES:

      I. The proportion of patients who experienced at least one such bleeding event within 6
      months of beginning treatment.

      II. Venous thromboembolism (VTE) recurrence including deep vein thrombosis (DVT), pulmonary
      embolism (PE), fatal PE, or arterial thromboembolism.

      OUTLINE: Patients are randomized to 1 of 2 groups.

      GROUP I: Patients receive lower dose apixaban orally (PO) twice daily (BID) for 365 days.

      GROUP II: Patients receive higher dose apixaban PO BID for 365 days.

      After completion of study treatment, patients are followed up for 12 months.
    
  